Selumetinib, a selective, oral small molecule inhibitor of MEK1/2, has shown a 40% sustained response rate (complete or partial response) in a phase 2 trial of children with progressive PAs harboring KIAA1549::BRAF fusions or BRAFV600E mutations (19). Here, BRAF is linked to gonorrhea.